LU93078I2 - Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib - Google Patents
Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib Download PDFInfo
- Publication number
- LU93078I2 LU93078I2 LU93078C LU93078C LU93078I2 LU 93078 I2 LU93078 I2 LU 93078I2 LU 93078 C LU93078 C LU 93078C LU 93078 C LU93078 C LU 93078C LU 93078 I2 LU93078 I2 LU 93078I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- solvates
- pharmaceutically acceptable
- acceptable salts
- combimetinib
- possibly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72457805P | 2005-10-07 | 2005-10-07 | |
US80284006P | 2006-05-23 | 2006-05-23 | |
PCT/US2006/039126 WO2007044515A1 (fr) | 2005-10-07 | 2006-10-05 | Inhibiteurs de mek et procedes pour les utiliser |
Publications (1)
Publication Number | Publication Date |
---|---|
LU93078I2 true LU93078I2 (fr) | 2016-07-19 |
Family
ID=37728416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU93078C LU93078I2 (fr) | 2005-10-07 | 2016-05-19 | Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib |
Country Status (32)
Country | Link |
---|---|
US (8) | US7803839B2 (fr) |
EP (1) | EP1934174B1 (fr) |
JP (8) | JP5129143B2 (fr) |
KR (2) | KR20130058072A (fr) |
CN (5) | CN104892582B (fr) |
AT (1) | ATE504565T1 (fr) |
AU (1) | AU2006302415B2 (fr) |
BR (1) | BRPI0617165B1 (fr) |
CA (3) | CA3052368A1 (fr) |
CY (2) | CY1111670T1 (fr) |
DE (1) | DE602006021205D1 (fr) |
DK (1) | DK1934174T3 (fr) |
EA (3) | EA019983B1 (fr) |
ES (1) | ES2365070T3 (fr) |
FR (1) | FR16C0021I2 (fr) |
GE (1) | GEP20125456B (fr) |
HK (2) | HK1119698A1 (fr) |
HR (1) | HRP20110498T1 (fr) |
HU (1) | HUS1600021I1 (fr) |
IL (5) | IL189900A (fr) |
LT (1) | LTC1934174I2 (fr) |
LU (1) | LU93078I2 (fr) |
MY (1) | MY162174A (fr) |
NL (1) | NL300809I2 (fr) |
NO (4) | NO347091B1 (fr) |
NZ (1) | NZ567140A (fr) |
PL (1) | PL1934174T3 (fr) |
PT (1) | PT1934174E (fr) |
RS (1) | RS51782B (fr) |
SI (1) | SI1934174T1 (fr) |
WO (1) | WO2007044515A1 (fr) |
ZA (1) | ZA200802075B (fr) |
Families Citing this family (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101318012B1 (ko) * | 2004-10-20 | 2013-10-14 | 메르크 세로노 에스.에이. | 3-아릴아미노 피리딘 유도체 |
EA019983B1 (ru) * | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
AU2007284562B2 (en) * | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
WO2008055236A2 (fr) | 2006-10-31 | 2008-05-08 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase mapk/erk |
WO2008076415A1 (fr) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Procédés d'utilisation d'inhibiteurs de mek |
WO2008124085A2 (fr) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2 |
KR20100009582A (ko) * | 2007-05-10 | 2010-01-27 | 화이자 리미티드 | 아제티딘 유도체 및 프로스타글란딘 e2 길항제로서 그의 용도 |
PE20140614A1 (es) | 2007-07-16 | 2014-05-28 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
CA2692819A1 (fr) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Anticorps anti-cd79b humanises, immunoconjugues, et procedes d'utilisation |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
WO2009093008A1 (fr) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
SI2247620T1 (sl) | 2008-01-31 | 2016-09-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
EP3692988A3 (fr) | 2008-03-18 | 2020-10-14 | Genentech, Inc. | Combinaisons d'un conjugué de médicament-anticorps anti-her2 et 5-fu, anticorps anti-vegf, carboplatin ou abt869 et procédés d'utilisation |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
EP2310373A1 (fr) * | 2008-07-01 | 2011-04-20 | Genentech, Inc. | Hétérocycles bicycliques en tant qu'inhibiteurs de mek kinase |
RU2495028C2 (ru) | 2008-07-01 | 2013-10-10 | Дженентек, Инк. | Изоиндолоны и способы их применения |
JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Mek阻害剤に対する耐性を付与するmek突然変異 |
JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用 |
CA2761445A1 (fr) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Composes pyrimidines bicycliques inhibiteurs de pi3k selectifs pour p110 delta, et procedes d'utilisation |
KR101428346B1 (ko) | 2009-09-28 | 2014-08-07 | 에프. 호프만-라 로슈 아게 | 벤즈옥사제핀 pi3k 억제 화합물 및 사용 방법 |
JP5546636B2 (ja) | 2009-09-28 | 2014-07-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾキセピンpi3k阻害剤化合物及び使用方法 |
NZ599939A (en) * | 2009-10-12 | 2014-02-28 | Hoffmann La Roche | Combinations of a pi3k inhibitor and a mek inhibitor |
CN102596951B (zh) | 2009-11-04 | 2015-04-15 | 诺华股份有限公司 | 用作mek抑制剂的杂环磺酰胺衍生物 |
US20110165155A1 (en) | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
EP2526102B1 (fr) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibiteurs de la PI3 kinase |
CA2786294A1 (fr) | 2010-02-22 | 2011-08-25 | F. Hoffmann-La Roche Ag | Composes de pyrido[3,2-d]pyrimidine inhibiteurs de pi3k delta et procedes d'utilisation |
MX360932B (es) | 2010-02-25 | 2018-11-21 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳-法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
WO2011121317A1 (fr) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo[1,2-b][1,2,3]thiadiazoles en tant qu'inhibiteurs de la kinase protéique ou de la kinase lipidique |
MA34234B1 (fr) | 2010-04-07 | 2013-05-02 | Hoffmann La Roche | Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation |
PE20130342A1 (es) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
CA3034600C (fr) | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Composes de pyridone et d'aza-pyridone et leurs procedes d'utilisation |
US8293736B2 (en) | 2010-07-14 | 2012-10-23 | F. Hoffmann La Roche Ag | Purine compounds selective for PI3K P110 delta, and methods of use |
EP2598661B1 (fr) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
CA2809836C (fr) | 2010-09-01 | 2019-01-15 | Gilead Connecticut, Inc. | Pyridinones/pyrazinones, methodes de fabrication, et methode d'utilisation associee pour le traitement de troubles medies par la tyrosine kinase de bruton |
CA2809662C (fr) | 2010-09-01 | 2019-04-16 | Gilead Connecticut, Inc. | Pyridazinones, leur procede de fabrication et leur procede d'utilisation |
WO2012052745A1 (fr) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinaisons d'inhibiteurs de pi3k avec un second agent antitumoral |
WO2012068096A2 (fr) | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs méthodes d'utilisation et de fabrication |
NZ609448A (en) | 2010-12-16 | 2015-07-31 | Hoffmann La Roche | Tricyclic pi3k inhibitor compounds and methods of use |
JP5766820B2 (ja) | 2011-02-09 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pi3キナーゼ阻害剤としての複素環化合物 |
BR112013024122A2 (pt) | 2011-03-21 | 2019-09-24 | Hoffmann La Roche | compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso |
CN102718750B (zh) * | 2011-03-31 | 2015-03-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含吖啶环的氨基吡啶类衍生物及其用途 |
CN103874689B (zh) | 2011-04-01 | 2016-04-27 | 基因泰克公司 | Akt抑制剂化合物和威罗菲尼的组合及使用方法 |
CN103841976A (zh) | 2011-04-01 | 2014-06-04 | 基因泰克公司 | Akt和mek抑制剂化合物的组合及其使用方法 |
EP2524918A1 (fr) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines en tant qu'inhibiteurs de kinase |
RU2598840C2 (ru) | 2011-05-19 | 2016-09-27 | Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii | Новые соединения |
CN103582479A (zh) | 2011-06-03 | 2014-02-12 | 霍夫曼-拉罗奇有限公司 | 用pi3k抑制剂化合物治疗间皮瘤的方法 |
MY193562A (en) * | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
JP6133291B2 (ja) | 2011-08-12 | 2017-05-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピラゾロ[3,4−c]ピリジン化合物と使用方法 |
KR20140074964A (ko) | 2011-09-27 | 2014-06-18 | 에프. 호프만-라 로슈 아게 | 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법 |
PT2750713E (pt) | 2011-10-14 | 2016-01-20 | Genentech Inc | Pirrolobenzodiazepinas e conjugados das mesmas |
WO2013063001A1 (fr) * | 2011-10-28 | 2013-05-02 | Genentech, Inc. | Associations thérapeutiques et méthodes de traitement du mélanome |
ES2552514T3 (es) | 2011-11-03 | 2015-11-30 | Hoffmann-La Roche Ag | Compuestos bicíclicos de piperazina |
BR112014010439A2 (pt) | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
WO2013067264A1 (fr) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Composés 8-fluorophtalazin-1(2h)-one comme inhibiteurs de l'activité btk |
EP2592103A1 (fr) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Dérivés d'aldéhyde de polymère |
CA2856873A1 (fr) | 2011-11-23 | 2013-05-30 | Igenica, Inc. | Anticorps anti-cd98 et leurs procedes d'utilisation |
WO2013082511A1 (fr) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Procédés pour surmonter la résistance tumorale aux antagonistes de vegf |
CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
CA2863427C (fr) | 2012-02-01 | 2022-07-12 | The Governors Of The University Of Alberta | Utilisation de pdgfr-alpha en tant que marqueur de diagnostic pour le cancer de la thyroide papillaire |
WO2013169858A1 (fr) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse |
BR112014028376A2 (pt) | 2012-06-08 | 2018-04-24 | Hoffmann La Roche | métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção |
RU2665462C2 (ru) | 2012-06-27 | 2018-08-30 | Ф. Хоффманн-Ля Рош Аг | Соединения 5-азаиндазола и способы их применения |
KR20150032886A (ko) | 2012-08-02 | 2015-03-30 | 제넨테크, 인크. | 항-etbr 항체 및 면역접합체 |
BR112015002193A2 (pt) | 2012-08-02 | 2017-07-04 | Genentech Inc | anticorpos anti-etbr e imunoconjugados |
JP6320382B2 (ja) | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | メラノーマの処置および診断 |
ES2743427T3 (es) | 2012-08-17 | 2020-02-19 | Hoffmann La Roche | Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib |
WO2014033196A1 (fr) | 2012-08-30 | 2014-03-06 | F. Hoffmann-La Roche Ag | Composés dioxino- et oxazine-[2,3-d]pyrimidine, inhibiteurs de pi3k, et leurs procédés d'utilisation |
KR102281288B1 (ko) | 2012-09-26 | 2021-07-26 | 에프. 호프만-라 로슈 아게 | 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법 |
WO2014059028A1 (fr) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anticorps anti-c16orf54 et leurs méthodes d'utilisation |
KR101995621B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항-cd22 항체 컨주게이트 |
CA2887895C (fr) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Conjugues d'anticorps cd19-anti-pyrrolobenzodiazepine |
CA2885315C (fr) | 2012-10-12 | 2020-06-23 | Spirogen Sarl | Pyrrolobenzodiazepines et leurs conjugues |
ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
RS53818B1 (en) | 2012-10-12 | 2015-06-30 | Spirogen Sàrl | PIROLOBENZODIAZEPINI I NJIHOVI conjugated |
WO2014057120A1 (fr) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Conjugués anticorps - pyrrolobenzodiazépine |
JP6270859B2 (ja) | 2012-10-12 | 2018-01-31 | エイディーシー・セラピューティクス・エス・アー・エール・エルAdc Therapeutics Sarl | ピロロベンゾジアゼピン−抗体結合体 |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
MY186549A (en) * | 2012-10-12 | 2021-07-26 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
WO2014074785A1 (fr) | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Procédés de prédiction de l'issue et du traitement du cancer du sein |
CA2889381C (fr) * | 2012-11-15 | 2023-01-03 | Duquesne University Of The Holy Ghost | Inhibiteurs de mek sous forme de promedicaments a base d'ester d'acide carboxylique |
TW201441193A (zh) * | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | 吡啶酮化合物 |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
CN110452242A (zh) | 2012-12-21 | 2019-11-15 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
SI2958944T1 (sl) | 2013-02-22 | 2019-08-30 | Abb Vie Stemcentrx Llc | Konjugati protiDLL3-protitelo-PBD in njihove uporabe |
ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
KR102057755B1 (ko) | 2013-03-13 | 2019-12-19 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
CA2905181C (fr) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee |
SG11201507477XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
CA2909510C (fr) | 2013-03-15 | 2024-04-02 | Cancer Research Technology, Llc | Procedes et compositions pour une modulation de cycle gamma-glutamyle |
JP6570512B2 (ja) | 2013-03-22 | 2019-09-04 | ユニバーシティ・オブ・ハワイUniversity Of Hawaii | 新規なStat3阻害剤 |
EP3003390B1 (fr) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anticorps anti-c10orf54 et leurs utilisations |
CN105491883B (zh) | 2013-06-13 | 2018-11-02 | 生物马特里卡公司 | 细胞稳定化 |
CA2912359A1 (fr) | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Composes heteroaryl pyridone et aza-pyridone amide |
EP3892294A1 (fr) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Procédés et compositions de conjugaison d'anticorps spécifique à un site |
US9532987B2 (en) * | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
EP3054983B1 (fr) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépines |
KR101813830B1 (ko) | 2013-12-05 | 2017-12-29 | 에프. 호프만-라 로슈 아게 | 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물 |
US10214584B2 (en) | 2014-01-15 | 2019-02-26 | Order-Made Medical Research Inc. | Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody |
CN104788365B (zh) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
JP6554480B2 (ja) | 2014-03-18 | 2019-07-31 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | オキセパン−2−イル−ピラゾール−4−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
CA2946112C (fr) | 2014-04-18 | 2020-11-24 | The Governors Of The University Of Alberta | Therapie ciblee pour restaurer le transport de l'iode radioactif pour traiter le cancer de la thyroide |
KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
WO2015172073A1 (fr) | 2014-05-08 | 2015-11-12 | Cornell University | Gels bioadhésifs et procédés d'utilisation |
WO2015182734A1 (fr) * | 2014-05-30 | 2015-12-03 | 協和発酵キリン株式会社 | Composé hétérocyclique contenant de l'azote |
JP6661554B2 (ja) | 2014-06-10 | 2020-03-11 | バイオマトリカ,インク. | 周囲温度における血小板の安定化 |
PL3169361T3 (pl) | 2014-07-15 | 2019-11-29 | Hoffmann La Roche | Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek |
WO2016037644A1 (fr) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazépines et leurs conjugués |
KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
DK3191135T3 (da) | 2014-09-12 | 2020-10-12 | Genentech Inc | Anti-HER2-antistoffer og immunokonjugater |
JP6730261B2 (ja) | 2014-09-17 | 2020-07-29 | ジェネンテック, インコーポレイテッド | 抗her2抗体を含む免疫複合体 |
CA2959689A1 (fr) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Pyrrolobenzodiazepines et conjugues a base de disulfure d'anticorps associes |
CN111303159A (zh) | 2014-10-02 | 2020-06-19 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
TW201625243A (zh) | 2014-10-14 | 2016-07-16 | 艾克塞里克斯公司 | 用於治療黑素瘤之藥物組合 |
EP3223854A1 (fr) | 2014-11-25 | 2017-10-04 | ADC Therapeutics SA | Conjugués anticorps-pyrrolobenzodiazépine |
US10766959B2 (en) | 2014-12-11 | 2020-09-08 | Pierre Fabre Medicament | Anti-C10ORF54 antibodies and uses thereof |
WO2016095088A1 (fr) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Inhibiteurs d'erk |
WO2016095089A1 (fr) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Inhibiteurs d'erk |
KR20230113416A (ko) | 2014-12-18 | 2023-07-28 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도 |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
WO2016205176A1 (fr) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Anticorps et immunoconjugués |
AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
HRP20240045T1 (hr) | 2015-06-30 | 2024-03-29 | Genentech, Inc. | Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta |
JP6522807B2 (ja) | 2015-07-02 | 2019-05-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法 |
EP3567045B1 (fr) | 2015-07-02 | 2022-01-12 | F. Hoffmann-La Roche AG | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ,インコーポレイテッド | グリカンアレイおよび使用の方法 |
CN108601839B (zh) | 2015-11-03 | 2021-10-26 | 基因泰克公司 | 用于治疗癌症的Bcl-2抑制剂和MEK抑制剂组合产品 |
WO2017087280A1 (fr) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Procédés de traitement d'un cancer positif her2 |
AU2016355320B2 (en) | 2015-11-19 | 2023-12-07 | Genentech, Inc. | Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors |
SG11201804776SA (en) | 2015-12-08 | 2018-07-30 | Biomatrica Inc | Reduction of erythrocyte sedimentation rate |
CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CA3236518A1 (fr) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Compositions de formes galeniques comprenant un inhibiteur de la tyrosine kinase de bruton |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
TWI780045B (zh) | 2016-03-29 | 2022-10-11 | 台灣浩鼎生技股份有限公司 | 抗體、醫藥組合物及方法 |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
EP3443114A1 (fr) | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Procédés diagnostiques et thérapeutiques relatifs au cancer |
CN109379889A (zh) | 2016-04-22 | 2019-02-22 | 台湾浩鼎生技股份有限公司 | 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法 |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
JP7018026B2 (ja) | 2016-06-16 | 2022-02-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
CN109843882A (zh) | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
BR112019001656A2 (pt) | 2016-07-27 | 2019-05-28 | Obi Pharma Inc | composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo |
CN106220607B (zh) * | 2016-07-27 | 2018-09-18 | 成都百事兴科技实业有限公司 | 一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法 |
CN110062767B (zh) | 2016-07-29 | 2023-07-11 | 台湾浩鼎生技股份有限公司 | 人抗体、药物组合物和方法 |
EP3496752B1 (fr) | 2016-08-12 | 2022-05-18 | Genentech, Inc. | Polythérapie avec un inhibiteur de mek, un inhibiteur de l'axe pd-1 et un inhibiteur de vegf |
JP2019534251A (ja) | 2016-09-29 | 2019-11-28 | ジェネンテック, インコーポレイテッド | Mek阻害剤、pd−1軸阻害剤、及びタキサンを用いた併用療法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
CN110290800A (zh) | 2016-11-21 | 2019-09-27 | 台湾浩鼎生技股份有限公司 | 缀合生物分子、医药组合物及方法 |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
DK3579883T3 (da) | 2017-02-08 | 2021-09-06 | Adc Therapeutics Sa | Pyrrolobenzodiazepin-antistofkonjugater |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
CN106866624B (zh) * | 2017-02-27 | 2017-12-26 | 济宁医学院 | 一种卡比替尼的化学合成方法 |
CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
CA3057744A1 (fr) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Polytherapie avec un conjugue anticorps-medicament anti-cd25 |
CN110536703A (zh) | 2017-04-20 | 2019-12-03 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
JP2020523384A (ja) | 2017-06-14 | 2020-08-06 | アーデーセー セラピューティクス ソシエテ アノニム | 抗cd25 adcを投与するための投与レジメ |
SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
EP3679159A1 (fr) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Méthodes diagnostiques et thérapeutiques du cancer |
US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
TW202003020A (zh) | 2018-03-21 | 2020-01-16 | 美國科羅拉多州立大學研究基金會 | 癌症疫苗組合物及其使用方法 |
WO2019188595A1 (fr) | 2018-03-26 | 2019-10-03 | 富士フイルム株式会社 | Composition de résine photosensible, procédé de production associé, film de réserve, procédé de formation de motif et procédé de production d'un dispositif électronique |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
WO2019224275A1 (fr) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Adjuvant moléculaire |
WO2020006176A1 (fr) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Variants de glycosynthases pour génie des glycoprotéines et leurs procédés d'utilisation |
GB201811364D0 (en) | 2018-07-11 | 2018-08-29 | Adc Therapeutics Sa | Combination therapy |
AU2019306165A1 (en) | 2018-07-20 | 2021-02-25 | Pierre Fabre Medicament | Receptor for vista |
AU2019332979A1 (en) | 2018-08-31 | 2021-02-11 | Adc Therapeutics Sa | Combination therapy |
CN112867803A (zh) | 2018-10-16 | 2021-05-28 | 诺华股份有限公司 | 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答 |
AU2019384645A1 (en) * | 2018-11-20 | 2021-06-10 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
MA55143A (fr) * | 2018-11-20 | 2021-09-29 | H Lee Moffitt Cancer Center & Res Institute Inc | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau |
AU2019383311A1 (en) * | 2018-11-20 | 2021-06-10 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
WO2020109251A1 (fr) | 2018-11-29 | 2020-06-04 | Adc Therapeutics Sa | Régime posologique |
GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
EP3899048A1 (fr) | 2018-12-19 | 2021-10-27 | ADC Therapeutics SA | Résistance à la pyrrolobenzodiazépine |
CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
WO2020187674A1 (fr) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
ES2930295T3 (es) | 2019-03-29 | 2022-12-09 | Medimmune Ltd | Compuestos y conjugados de los mismos |
TWI735210B (zh) | 2019-04-26 | 2021-08-01 | 中國醫藥大學 | Adam9抑制劑作為免疫調節劑之用途 |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
JP2022536140A (ja) | 2019-06-10 | 2022-08-12 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
EP3980079A1 (fr) | 2019-06-10 | 2022-04-13 | ADC Therapeutics SA | Polythérapie comprenant un conjugué médicament-anticorps anti-cd19 et un inhibiteur de pi3k ou un agent secondaire |
CA3147397A1 (fr) | 2019-07-22 | 2021-01-28 | Lupin Limited | Composes macrocycliques utilises en tant qu'agonistes sting et procedes et utilisations de ceux-ci |
GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
US20240123081A1 (en) | 2019-10-25 | 2024-04-18 | Medimmune, Llc | Branched moiety for use in conjugates |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
CN111170990B (zh) * | 2020-01-16 | 2021-01-05 | 广州科锐特生物科技有限公司 | 一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法 |
KR20220130749A (ko) | 2020-01-22 | 2022-09-27 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
TW202140076A (zh) | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
WO2021206167A1 (fr) | 2020-04-10 | 2021-10-14 | 大鵬薬品工業株式会社 | Thérapie contre le cancer à l'aide d'un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de mek |
US11701427B2 (en) | 2020-04-16 | 2023-07-18 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
EP3915576A1 (fr) | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Récepteurs d'antigène chimérique spécifiques pour p95her2 et leurs utilisations |
EP3939999A1 (fr) | 2020-07-14 | 2022-01-19 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
GB202012161D0 (en) | 2020-08-05 | 2020-09-16 | Adc Therapeutics Sa | Combination therapy |
WO2022036171A1 (fr) | 2020-08-14 | 2022-02-17 | Newave Pharmaceutical Inc. | Compositions de forme posologique comprenant un inhibiteur de btk et des mutants de celui-ci |
GB202015226D0 (en) | 2020-09-25 | 2020-11-11 | Adc Therapeutics S A | Pyrrol obenzodiazepine-antibody conugates and uses thereof |
GB202015916D0 (en) | 2020-10-07 | 2020-11-18 | Adc Therapeutics Sa | Combination therapy |
WO2022079211A1 (fr) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugués |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
KR20230156731A (ko) | 2021-03-09 | 2023-11-14 | 제넨테크, 인크. | 뇌암 치료에 이용하기 위한 벨바라페닙 |
WO2022195551A1 (fr) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarqueurs pour le cancer et leurs méthodes d'utilisation |
JP2024514112A (ja) | 2021-04-06 | 2024-03-28 | ジェネンテック, インコーポレイテッド | ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法 |
GB202107713D0 (en) | 2021-05-28 | 2021-07-14 | Medimmune Ltd | Combination therapy |
GB202107706D0 (en) | 2021-05-28 | 2021-07-14 | Adc Therapeutics S A | Combination therapy |
GB202107709D0 (en) | 2021-05-28 | 2021-07-14 | Adc Therapeutics S A | Combination therapy |
KR20240008410A (ko) | 2021-06-09 | 2024-01-18 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 병용요법 |
AU2022302769A1 (en) | 2021-06-29 | 2024-02-08 | Adc Therapeutics Sa | Combination therapy using antibody-drug conjugates |
WO2023057545A1 (fr) | 2021-10-06 | 2023-04-13 | Microquin Ltd. | Chalcones substitués |
WO2023078881A1 (fr) | 2021-11-04 | 2023-05-11 | F. Hoffmann-La Roche Ag | Nouvelle utilisation d'un composé quinazolinone pour le traitement du cancer |
WO2023111213A1 (fr) | 2021-12-16 | 2023-06-22 | Rdp Pharma Ag | Polypeptides de pénétration cellulaire (cpps) et leur utilisation en thérapie humaine |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
WO2023178266A2 (fr) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Composés phénylamino fluorés et compositions pharmaceutiques |
EP4253418A1 (fr) | 2022-03-29 | 2023-10-04 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Cellules immunitaires exprimant des récepteurs d'antigène chimérique et anticorps bispécifiques et leurs utilisations |
GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
WO2024033381A1 (fr) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition de tcf4/itf2 dans le traitement du cancer |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
JPH03192592A (ja) | 1989-12-21 | 1991-08-22 | Matsushita Electric Ind Co Ltd | 磁気テープ記録再生装置 |
CA2186947A1 (fr) | 1994-04-01 | 1995-10-12 | Kazuo Ueda | Derive d'oxime et bactericide le contenant en tant qu'ingredient actif |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
WO1998037881A1 (fr) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek |
DE69836378T2 (de) * | 1997-07-01 | 2007-10-11 | Warner-Lambert Co. Llc | Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren |
WO1999001426A1 (fr) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | Derives d'acide benzhydroxamique phenylamino 4-bromo ou 4-iodo et utilisation de ces derniers en tant qu'inhibiteurs de mek |
US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
EP1140046A1 (fr) | 1998-12-15 | 2001-10-10 | Warner-Lambert Company | Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek |
EP1143957A3 (fr) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Traitement de l'arthrite a l'aide d'inhibiteurs de la mek |
ATE310567T1 (de) | 1998-12-22 | 2005-12-15 | Warner Lambert Co | Chemotheriapie mit einem antimitotischen mittel und einem mek inhibitor |
KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
CA2358438A1 (fr) | 1999-01-07 | 2000-07-13 | David Thomas Dudley | Methode antivirale utilisant des inhibiteurs de mek |
BR9916785A (pt) | 1999-01-07 | 2001-10-23 | Warner Lambert Co | Tratamento de asma com inibidores mek |
CN1149204C (zh) | 1999-01-13 | 2004-05-12 | 沃尼尔·朗伯公司 | 1-杂环取代的二芳基胺 |
WO2000042003A1 (fr) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek |
CA2348236A1 (fr) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek |
CA2349180A1 (fr) * | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4'heteroaryle diarylamines |
ID30439A (id) * | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
CA2378381A1 (fr) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Traitement de douleurs chroniques au moyen d'inhibiteurs de mek |
EP1202732A2 (fr) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Methode de traitement de la douleur chronique utilisant des inhibiteurs mek |
KR20020015376A (ko) | 1999-07-16 | 2002-02-27 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Mek 억제제를 사용한 만성 통증의 치료 방법 |
NZ515567A (en) | 1999-07-16 | 2004-03-26 | Warner Lambert Co | Method for treating chronic pain using MEK inhibitors |
NZ517829A (en) | 1999-09-17 | 2004-12-24 | Millennium Pharm Inc | Benzamides and related inhibitors of factor Xa |
CA2403017A1 (fr) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | Diarylamines a substitution 5-amide, utilises en tant qu'inhibiteur de kinases erk mitogenes mek |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
SI1301472T1 (sl) | 2000-07-19 | 2014-05-30 | Warner-Lambert Company Llc | Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
JP2003192592A (ja) | 2001-10-17 | 2003-07-09 | Sankyo Co Ltd | 医薬組成物 |
BR0213696A (pt) | 2001-10-31 | 2004-10-26 | Pfizer Prod Inc | Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas |
DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
PT2275102E (pt) * | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
TW200406203A (en) * | 2002-03-13 | 2004-05-01 | Array Biopharma Inc | N3 alkylated banzimidazole derivatives as MEK inhibitors |
WO2003103590A2 (fr) | 2002-06-11 | 2003-12-18 | Merck & Co., Inc. | Inhibiteurs de la kinase p38 (halo-benzo carbonyl)heterobicyclique |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
JP4617299B2 (ja) | 2003-03-03 | 2011-01-19 | アレイ バイオファーマ、インコーポレイテッド | p38阻害剤及びその使用法 |
JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
EP1641804A1 (fr) * | 2003-06-20 | 2006-04-05 | Celltech R & D Limited | Derives de thienopyridone en tant qu inhibiteurs de kinase |
WO2005000818A1 (fr) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek |
WO2005007616A1 (fr) | 2003-07-23 | 2005-01-27 | Warner-Lambert Company Llc | Derives de diphenylaminocetone utiles comme inhibiteurs de mek |
US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
WO2005009975A2 (fr) | 2003-07-24 | 2005-02-03 | Warner-Lambert Company Llc | Benzimidazoles n-methyle-substitues |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
TW200520745A (en) | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
WO2005051301A2 (fr) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
ATE384058T1 (de) * | 2003-12-08 | 2008-02-15 | Hoffmann La Roche | Thiazolderivate |
MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
AR050084A1 (es) | 2004-07-27 | 2006-09-27 | Novartis Ag | Derivados de bencimidazolona como inhibidores de hsp90 |
KR101318012B1 (ko) * | 2004-10-20 | 2013-10-14 | 메르크 세로노 에스.에이. | 3-아릴아미노 피리딘 유도체 |
WO2006061712A2 (fr) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
EA019983B1 (ru) * | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
AU2007284562B2 (en) * | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
-
2006
- 2006-10-05 EA EA200801041A patent/EA019983B1/ru active Protection Beyond IP Right Term
- 2006-10-05 CA CA3052368A patent/CA3052368A1/fr not_active Abandoned
- 2006-10-05 DK DK06825554.6T patent/DK1934174T3/da active
- 2006-10-05 EA EA201400111A patent/EA025871B9/ru not_active IP Right Cessation
- 2006-10-05 JP JP2008534706A patent/JP5129143B2/ja active Active
- 2006-10-05 CN CN201510197206.2A patent/CN104892582B/zh active Active
- 2006-10-05 WO PCT/US2006/039126 patent/WO2007044515A1/fr active Application Filing
- 2006-10-05 EA EA201691142A patent/EA032466B1/ru unknown
- 2006-10-05 NO NO20200035A patent/NO347091B1/no unknown
- 2006-10-05 CN CN201910851634.0A patent/CN110668988A/zh active Pending
- 2006-10-05 US US11/995,928 patent/US7803839B2/en active Active
- 2006-10-05 CA CA2622755A patent/CA2622755C/fr active Active
- 2006-10-05 KR KR1020137010590A patent/KR20130058072A/ko not_active Application Discontinuation
- 2006-10-05 NZ NZ567140A patent/NZ567140A/en unknown
- 2006-10-05 SI SI200631043T patent/SI1934174T1/sl unknown
- 2006-10-05 CA CA2927656A patent/CA2927656C/fr active Active
- 2006-10-05 CN CN201310366896.0A patent/CN103524392B/zh active Active
- 2006-10-05 CN CN2006800449476A patent/CN101365676B/zh active Active
- 2006-10-05 CN CN201810489110.7A patent/CN109053523B/zh active Active
- 2006-10-05 AT AT06825554T patent/ATE504565T1/de active
- 2006-10-05 BR BRPI0617165A patent/BRPI0617165B1/pt active IP Right Grant
- 2006-10-05 MY MYPI20080982A patent/MY162174A/en unknown
- 2006-10-05 DE DE602006021205T patent/DE602006021205D1/de active Active
- 2006-10-05 GE GEAP200610685A patent/GEP20125456B/en unknown
- 2006-10-05 RS RS20110277A patent/RS51782B/en unknown
- 2006-10-05 PL PL06825554T patent/PL1934174T3/pl unknown
- 2006-10-05 ES ES06825554T patent/ES2365070T3/es active Active
- 2006-10-05 AU AU2006302415A patent/AU2006302415B2/en active Active
- 2006-10-05 PT PT06825554T patent/PT1934174E/pt unknown
- 2006-10-05 EP EP06825554A patent/EP1934174B1/fr active Active
-
2008
- 2008-03-03 IL IL189900A patent/IL189900A/en active Protection Beyond IP Right Term
- 2008-03-05 ZA ZA200802075A patent/ZA200802075B/xx unknown
- 2008-04-04 KR KR1020087008141A patent/KR101341792B1/ko active Protection Beyond IP Right Term
- 2008-05-05 NO NO20082088A patent/NO344876B1/no active Protection Beyond IP Right Term
- 2008-11-25 HK HK08112886.4A patent/HK1119698A1/xx unknown
-
2010
- 2010-05-05 US US12/774,544 patent/US7915250B2/en active Active
-
2011
- 2011-03-15 US US13/048,832 patent/US8362002B2/en active Active
- 2011-07-04 CY CY20111100646T patent/CY1111670T1/el unknown
- 2011-07-05 HR HR20110498T patent/HRP20110498T1/hr unknown
-
2012
- 2012-09-05 JP JP2012195223A patent/JP5678019B2/ja active Active
-
2013
- 2013-06-27 US US13/929,062 patent/US20140275527A1/en not_active Abandoned
- 2013-10-30 IL IL229136A patent/IL229136A/en active IP Right Grant
-
2014
- 2014-03-13 JP JP2014049674A patent/JP5856211B2/ja active Active
- 2014-06-10 IL IL233053A patent/IL233053A0/en unknown
-
2015
- 2015-02-05 US US14/615,079 patent/US20170166523A9/en not_active Abandoned
- 2015-09-24 JP JP2015186392A patent/JP2015232045A/ja active Pending
-
2016
- 2016-03-07 HK HK16102537.8A patent/HK1214595A1/zh unknown
- 2016-05-13 HU HUS1600021C patent/HUS1600021I1/hu unknown
- 2016-05-17 LT LTPA2016016C patent/LTC1934174I2/lt unknown
- 2016-05-18 CY CY2016015C patent/CY2016015I2/el unknown
- 2016-05-18 NL NL300809C patent/NL300809I2/nl unknown
- 2016-05-19 LU LU93078C patent/LU93078I2/fr unknown
- 2016-05-19 FR FR16C0021C patent/FR16C0021I2/fr active Active
-
2017
- 2017-03-02 JP JP2017038954A patent/JP2017101071A/ja active Pending
- 2017-03-15 IL IL251185A patent/IL251185A0/en unknown
-
2018
- 2018-01-17 JP JP2018005721A patent/JP2018058907A/ja not_active Withdrawn
- 2018-04-13 US US15/952,923 patent/US20190144382A1/en not_active Abandoned
- 2018-06-19 IL IL260127A patent/IL260127B/en unknown
-
2019
- 2019-02-25 JP JP2019031850A patent/JP2019089841A/ja not_active Withdrawn
- 2019-10-09 US US16/597,607 patent/US20200031770A1/en not_active Abandoned
-
2020
- 2020-04-20 US US16/853,043 patent/US11597699B2/en active Active
- 2020-08-21 JP JP2020139894A patent/JP2020189882A/ja active Pending
- 2020-09-04 NO NO2020031C patent/NO2020031I1/no unknown
-
2023
- 2023-05-11 NO NO2023022C patent/NO2023022I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU93078I2 (fr) | Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib | |
IN2012DN03085A (fr) | ||
IL189666A0 (en) | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) | |
TW200626553A (en) | Novel compounds | |
MX2010003868A (es) | Cis-imidazolinas quirales. | |
TW200639156A (en) | New compounds | |
TW200508207A (en) | New benzimidazole derivatives | |
DE60313350D1 (de) | Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer | |
UA96742C2 (en) | Mek inhibitors and use thereof | |
EA201990219A3 (ru) | Ингибиторы mek и способы их применения | |
DK1551850T3 (da) | 2"-oxo-voruscharin og derivater deraf | |
UA95250C2 (ru) | Пиридинаминосульфонил-замещенные бензамиды как ингибиторы цитохром р450 3а4 (cyp4503a4) |